{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:24:52Z","timestamp":1790011492021,"version":"4.0.1"},"reference-count":247,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/64895\/2009"],"award-info":[{"award-number":["SFRH\/BD\/64895\/2009"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/69378\/2010"],"award-info":[{"award-number":["SFRH\/BD\/69378\/2010"]}]},{"name":"FSE"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ejpb.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T14:32:28Z","timestamp":1396017148000},"page":"8-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":191,"title":["Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules"],"prefix":"10.1016","volume":"88","author":[{"given":"Ana","family":"Fortuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Serralheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2014.03.004_b0005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/157488507779422374","article-title":"Nasal drug delivery system-factors affecting and applications","volume":"2","author":"Jadhav","year":"2007","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume":"40","author":"Bitter","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal drug delivery \u2013 recent developments and future prospects","volume":"161","author":"Illum","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0025","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2014.03.004_b0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0973-8398.45032","article-title":"Bioavailability of intranasal drug delivery system","volume":"2","author":"Bhise","year":"2008","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03639040903170750","article-title":"The application of mucoadhesive polymers in nasal drug delivery","volume":"36","author":"Jiang","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.21793","article-title":"Non-invasive systemic drug delivery: developability considerations for alternate routes of administration","volume":"99","author":"Mathias","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijpharm.2012.04.007","article-title":"Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome","volume":"430","author":"Qiang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0055","series-title":"Drug Delivery to the Central Nervous System","first-page":"175","article-title":"Vesicular systems for intranasal drug delivery","author":"Alsarra","year":"2010"},{"key":"10.1016\/j.ejpb.2014.03.004_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","article-title":"Effects of physicochemical properties and other factors on systemic nasal drug delivery","volume":"29","author":"Behl","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.03.004_b0070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/js960503w","article-title":"Diffusion of drugs in native and purified gastrointestinal mucus","volume":"86","author":"Larhed","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0075","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: new developments and strategies","volume":"7","author":"Illum","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2014.03.004_b0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2010.12.037","article-title":"Differential expression of organic cation transporters in normal and polyps human nasal epithelium: implications for in vitro drug delivery studies","volume":"406","author":"Agu","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0085","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2014.03.004_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clinthera.2008.03.001","article-title":"Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study","volume":"30","author":"Christrup","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0095","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1034\/j.1399-6576.2002.460702.x","article-title":"Nasal administration of opioids for pain management in adults","volume":"46","author":"Dale","year":"2002","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.ejpb.2014.03.004_b0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1526-4610.2006.00301.x","article-title":"Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy","volume":"46","author":"Goadsby","year":"2006","journal-title":"Headache"},{"key":"10.1016\/j.ejpb.2014.03.004_b0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-5122(00)00175-4","article-title":"Clinical evaluation, dose-finding and acceptability of AERODIOL\u00ae, the pulsed estrogen therapy for treatment of climacteric symptoms","volume":"37","author":"Pelissier","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.ejpb.2014.03.004_b0110","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S0140-6736(98)06196-0","article-title":"Efficacy and acceptability of intranasal 17 \u00df-oestradiol for menopausal symptoms: randomised dose\u2013response study","volume":"353","author":"Studd","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2014.03.004_b0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0378-5122(00)00144-4","article-title":"Endometrial safety and tolerability of AERODIOL\u00ae (intranasal estradiol) for 1 year","volume":"36","author":"Gompel","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.ejpb.2014.03.004_b0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1067\/mob.2000.104843","article-title":"Clinical equivalence of intranasal and oral 17\u03b2-estradiol for postmenopausal symptoms","volume":"182","author":"Mattsson","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/humrep\/deh011","article-title":"Efficacy of pulsed estrogen therapy in relatively younger patients with surgically induced menopause","volume":"19","author":"Yesildaglar","year":"2004","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ejpb.2014.03.004_b0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10717540802035251","article-title":"Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation","volume":"15","author":"Alsarra","year":"2008","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1018903407592","article-title":"The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2\u2032-ester prodrugs","volume":"11","author":"Shao","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0140","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.etap.2008.10.007","article-title":"Development of atropine sulphate nasal drops and its pharmacokinetic and safety evaluation in healthy human volunteers","volume":"27","author":"Rajpal","year":"2009","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0145","first-page":"1","article-title":"Atropine aerosol spray (AAS) by nasal application in organophosphate poisoning","volume":"1","author":"\u00d6zyurt","year":"2003","journal-title":"J. Med. Chem. Def."},{"key":"10.1016\/j.ejpb.2014.03.004_b0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(00)00499-3","article-title":"Intranasal absorption of buprenorphine-in vivo bioavailability study in sheep","volume":"205","author":"Lindhardt","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(01)00591-9","article-title":"Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man","volume":"217","author":"Lindhardt","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10611861003663523","article-title":"Mucoadhesive chitosan microspheres of carvedilol for nasal administration","volume":"18","author":"Patil","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2014.03.004_b0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jbm.b.31947","article-title":"In vivo evaluation of alginate microspheres of carvedilol for nasal delivery","volume":"100","author":"Patil","year":"2012","journal-title":"J. Biomed. Mater. Res. B. Appl. Biomater."},{"key":"10.1016\/j.ejpb.2014.03.004_b0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-5173(02)00029-7","article-title":"Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam","volume":"237","author":"Li","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/bdd.314","article-title":"Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats","volume":"23","author":"Pelser","year":"2002","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2014.03.004_b0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejpb.2008.07.005","article-title":"Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting","volume":"70","author":"Wang","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jamp.2007.0672","article-title":"Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice","volume":"21","author":"Onischuk","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0190","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.clinthera.2009.05.022","volume":"31","author":"Kress","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10717540902764172","article-title":"Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation","volume":"16","author":"Tas","year":"2009","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijpharm.2006.07.038","article-title":"Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part II: safety of various absorption enhancers and pharmacokinetic evaluation","volume":"327","author":"Zaki","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejps.2007.08.006","article-title":"Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties","volume":"32","author":"Zaki","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0210","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1213\/01.ane.0000226150.90317.16","article-title":"Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers","volume":"103","author":"Wermeling","year":"2006","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejpb.2014.03.004_b0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eplepsyres.2008.10.005","article-title":"A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation","volume":"83","author":"Wermeling","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0220","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.2010.03611.x","article-title":"Pharmacokinetics and pharmacodynamics of nasally delivered midazolam","volume":"69","author":"Haschke","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery \u2013 possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1526-4637.2007.00300.x","article-title":"Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery","volume":"9","author":"Stoker","year":"2008","journal-title":"Pain Med."},{"key":"10.1016\/j.ejpb.2014.03.004_b0235","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1213\/ane.0b013e318187b952","article-title":"The analgesic efficacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model","volume":"107","author":"Christensen","year":"2008","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejpb.2014.03.004_b0240","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0168-3659(01)00553-3","article-title":"Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation","volume":"79","author":"Cheng","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0168-3659(99)00258-8","article-title":"Prolonged delivery of nicotine in rats via nasal administration of proliposomes","volume":"66","author":"Jung","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1248\/yakushi.121.355","article-title":"Evaluation of the method for nifedipine administration for a rapid onset of clinical effect: a clinical study in normal volunteers","volume":"121","author":"Kubota","year":"2001","journal-title":"Yakuga. Zasshi"},{"key":"10.1016\/j.ejpb.2014.03.004_b0255","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s002800051014","article-title":"Nasal absorption of ondansetron in rats: an alternative route of drug delivery","volume":"45","author":"Hussain","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0260","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0168-3659(94)00114-A","article-title":"Prolipossomes as an intranasal dosage form for the sustained delivery of propranolol","volume":"34","author":"Ahn","year":"1995","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0265","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1023\/A:1007551927177","article-title":"Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects","volume":"17","author":"Ahmed","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2014.03.004_b0275","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ajhp\/62.1.48","article-title":"Bioavailability of intranasal butorphanol administered from a single-dose sprayer","volume":"62","author":"Davis","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0280","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bdd.2510140503","article-title":"Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol","volume":"14","author":"Shyu","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2014.03.004_b0285","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.clinthera.2010.07.001","volume":"32","author":"Veldhorst-Janssen","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0290","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5414\/CPP48138","article-title":"Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188","volume":"48","author":"Fisher","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0295","doi-asserted-by":"crossref","first-page":"860","DOI":"10.5414\/CPP48860","article-title":"Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100\u2013800 \u03bcg in healthy volunteers","volume":"48","author":"Fisher","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10717540903447194","article-title":"In situ gels of metoclopramide hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits","volume":"17","author":"Mahajan","year":"2010","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0305","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/713840323","article-title":"Sodium alginate microspheres of metoprolol tartrate for intranasal systemic delivery: development and evaluation","volume":"10","author":"Rajinikanth","year":"2003","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0310","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0378-5173(97)00364-5","article-title":"The effect of a viscosity and an absorption enhancer on the intra nasal absorption of metoprolol in rats","volume":"163","author":"Kilian","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0315","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0304-3959(03)00318-X","article-title":"Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients","volume":"106","author":"Fitzgibbon","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.ejpb.2014.03.004_b0320","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.301.1.391","article-title":"Intranasal delivery of morphine","volume":"301","author":"Illum","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0325","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/10837450903479970","article-title":"Nasal administration of ondansetron using a novel microspheres delivery system. Part II: ex vivo and in vivo studies","volume":"15","author":"Mahajan","year":"2010","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0330","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3109\/03639040903517906","article-title":"Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes","volume":"36","author":"Gungor","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2007.07.028","article-title":"Formulation and evaluation of ondansetron nasal delivery systems","volume":"349","author":"Cho","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0340","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1208\/s12249-009-9213-6","article-title":"Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits","volume":"10","author":"Elshafeey","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2014.03.004_b0345","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2165\/00003088-200241110-00002","article-title":"Clinical pharmacokinetics of intranasal sumatriptan","volume":"4","author":"Fuseau","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2014.03.004_b0350","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1468-2982.1997.1704541.x","article-title":"Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses","volume":"17","author":"Moore","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejpb.2014.03.004_b0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0928-0987(97)00073-0","article-title":"Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration","volume":"6","author":"Duquesnoy","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0360","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1248\/cpb.59.1083","article-title":"Rapid and sensitive determination of udenafil in plasma by LC-MS\/MS for intranasal pharmacokinetic study in rats","volume":"59","author":"Ku","year":"2011","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejpb.2014.03.004_b0365","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00044011-200525030-00006","article-title":"Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects","volume":"25","author":"Uemura","year":"2005","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejpb.2014.03.004_b0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/joms.2000.17884","article-title":"Analgesic efficacy of intranasal butorphanol (Stadol NS) in the treatment of pain after dental impaction surgery","volume":"58","author":"Desjardins","year":"2000","journal-title":"J. Oral Maxilofac. Surg."},{"key":"10.1016\/j.ejpb.2014.03.004_b0375","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clinthera.2005.04.002","article-title":"Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"27","author":"Wermeling","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0380","first-page":"27","article-title":"An evaluation of the efficacy and safety of transnasal Butorphanol for post-hemorrhoidectomy pain relief","volume":"20","author":"Mai","year":"2009","journal-title":"J. Soc. Colon Rectal Surgeon (Taiwan)"},{"key":"10.1016\/j.ejpb.2014.03.004_b0385","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1399-6576.1991.tb03234.x","article-title":"Transnasal butorphanol: a new method for pain relief in post-cesarean section pain","volume":"35","author":"Abboud","year":"1991","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.ejpb.2014.03.004_b0390","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/ajhp\/61.3.261","article-title":"Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer","volume":"61","author":"Davis","year":"2004","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/PPA.S7665","article-title":"Intranasal fentanyl for pain control: current status with a focus on patient considerations","volume":"5","author":"Prommer","year":"2011","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ejpb.2014.03.004_b0400","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/1520-6017(200105)90:5<617::AID-JPS1018>3.0.CO;2-5","article-title":"Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir","volume":"90","author":"Yang","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0405","first-page":"51","article-title":"Chitosan nanoparticles: a promising system for drug delivery","volume":"11","author":"Tiyaboonchai","year":"2003","journal-title":"Naresuan Univ. J."},{"key":"10.1016\/j.ejpb.2014.03.004_b0410","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1248\/cpb.58.1423","article-title":"Chitosan nanoparticles: a promising system in novel drug delivery","volume":"58","author":"Nagpal","year":"2010","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2014.03.004_b0415","first-page":"68","article-title":"Enhanced bioavailability of drugs via intranasal drug delivery system","volume":"3","author":"Ali","year":"2012","journal-title":"Int. Res. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0420","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860500246217","article-title":"Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting","volume":"13","author":"Vyas","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2014.03.004_b0425","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1208\/pt070108","article-title":"Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan","volume":"7","author":"Vyas","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2014.03.004_b0430","first-page":"194","article-title":"A review on factors affecting the design of nasal drug delivery system","volume":"3","author":"Dhakar","year":"2011","journal-title":"Int. J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0435","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1111\/j.1526-4637.2006.00270.x","article-title":"The treatment of breakthrough pain","volume":"8","author":"McCarberg","year":"2007","journal-title":"Pain Med."},{"key":"10.1016\/j.ejpb.2014.03.004_b0440","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1399-6576.2008.01608.x","article-title":"A controlled comparison between single doses of intravenous and intramuscular morphine with respect to analgesic effects and patient safety","volume":"52","author":"Tveita","year":"2008","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.ejpb.2014.03.004_b0445","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2515\/therapie\/2010052","article-title":"Intranasal delivery of systemic drugs: a new route for opioid drugs","volume":"65","author":"Devillier","year":"2010","journal-title":"Therapie"},{"key":"10.1016\/j.ejpb.2014.03.004_b0450","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.clinthera.2009.12.015","article-title":"A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally","volume":"31","author":"Veldhorst-Janssen","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0455","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","article-title":"Evaluation of the clearance characteristics of bioadhesive systems in humans","volume":"178","author":"Soane","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0460","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5055\/jom.2010.0001","article-title":"Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain","volume":"6","author":"Kaasa","year":"2010","journal-title":"J. Opioid. Manag."},{"key":"10.1016\/j.ejpb.2014.03.004_b0465","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11095-009-0041-x","article-title":"Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy","volume":"27","author":"Jain","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0470","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1468-2982.2005.00966.x","article-title":"Distribution of intranasal 11C-zolmitriptan assessed by positron emission tomography","volume":"25","author":"Yates","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejpb.2014.03.004_b0475","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00126839-200506030-00002","article-title":"Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study","volume":"6","author":"Wall","year":"2005","journal-title":"Drugs RD"},{"key":"10.1016\/j.ejpb.2014.03.004_b0480","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00023210-200519020-00003","article-title":"Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study","volume":"19","author":"Dodick","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2014.03.004_b0485","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1526-4610.2005.05004.x","article-title":"Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine \u2013 results from phase 1 of the REALIZE Study","volume":"45","author":"Gawel","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.ejpb.2014.03.004_b0490","unstructured":"Drugs.com Imitrex Official FDA Information, Side Effects and Uses. <www.Drugs.com>."},{"key":"10.1016\/j.ejpb.2014.03.004_b0495","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/0002-8703(94)90391-3","article-title":"Intranasal delivery of cardiovascular agents: an innovative approach to cardiovascular pharmacotherapy","volume":"127","author":"Landau","year":"1994","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejpb.2014.03.004_b0500","first-page":"859","article-title":"The effect of intravenous nitroglycerine on blood pressure during intubation","volume":"19","author":"Firoozbakhsh","year":"2008","journal-title":"Middle East J. Anesthesiol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0505","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejpb.2014.03.004_b0510","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1442-2042.2004.00933.x","article-title":"Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose","volume":"11","author":"Deveci","year":"2004","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0515","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0520","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2008.09.005","article-title":"Nanoparticles for nasal vaccination","volume":"61","author":"Csaba","year":"2009","journal-title":"Adv. Drug. Deliv. Ver."},{"key":"10.1016\/j.ejpb.2014.03.004_b0525","first-page":"22","article-title":"Nasal cavity: a promising transmucosal platform for drug delivery and research approaches from nasal to brain targeting","volume":"2","author":"Singh","year":"2012","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0530","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-61779-310-3_20","article-title":"Intranasal delivery of neuropeptides","volume":"789","author":"Veronesi","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0535","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1139\/w2012-051","article-title":"Protective efficacy of a Mycoplasma pneumoniae P1C DNA vaccine fused with the B subunit of Escherichia coli heat-labile enterotoxin","volume":"58","author":"Zhu","year":"2012","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0540","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0973-8398.55041","article-title":"Recent trends in protein and peptide drug delivery systems","volume":"3","author":"Gupta","year":"2009","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0545","first-page":"367","article-title":"Noninvasive routes of proteins and peptides drug delivery","volume":"73","author":"Jitendra","year":"2011","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0550","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v29.i4.10","article-title":"Transcending the skin barrier to deliver peptides and proteins using active technologies","volume":"29","author":"Singh","year":"2012","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2014.03.004_b0555","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187221108783331429","article-title":"Recent patents review on intranasal administration for CNS drug delivery","volume":"2","author":"Jogani","year":"2008","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2014.03.004_b0560","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00198-006-0159-1","article-title":"Daily nasal spray of hPTH(1\u201334) for 3 months increases bone mass in osteoporotic subjects: a pilot study","volume":"17","author":"Matsumoto","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejpb.2014.03.004_b0565","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11914-010-0024-1","article-title":"Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men","volume":"8","author":"Devogelaer","year":"2010","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.ejpb.2014.03.004_b0570","doi-asserted-by":"crossref","first-page":"263","DOI":"10.18433\/J3CS3F","article-title":"Nasal delivery of recombinant human growth hormone: in vivo evaluation with Pheroid technology and N-trimethyl chitosan chloride","volume":"13","author":"Steyn","year":"2010","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0575","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/en.2011-1586","article-title":"Intranasal leptin reduces appetite and induces weight loss in rats with diet-induced obesity (DIO)","volume":"153","author":"Schulz","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejpb.2014.03.004_b0580","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1515\/dmdi.2011.007","article-title":"Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia","volume":"26","author":"Merelli","year":"2011","journal-title":"Drug Metabol. Drug Interact."},{"key":"10.1016\/j.ejpb.2014.03.004_b0585","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/187152412800229143","article-title":"Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment","volume":"12","author":"Parra","year":"2012","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.ejpb.2014.03.004_b0590","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0378-5173(01)00930-9","article-title":"Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers","volume":"233","author":"Teshima","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0595","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1463-1326.2007.00823.x","article-title":"PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db\/db mice","volume":"10","author":"Youn","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejpb.2014.03.004_b0600","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/10611860400000938","article-title":"Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration","volume":"12","author":"Lerner","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2014.03.004_b0605","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1745-7254.2005.00174.x","article-title":"Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo","volume":"26","author":"Zhang","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejpb.2014.03.004_b0610","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jconrel.2006.08.015","article-title":"Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin","volume":"115","author":"Yang","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0615","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1016\/j.vaccine.2010.03.062","article-title":"A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits","volume":"28","author":"Gao","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2014.03.004_b0620","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-beta to the monkey nervous system following intranasal administration","volume":"152","author":"Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejpb.2014.03.004_b0625","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1023\/A:1018997625726","article-title":"Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans","volume":"9","author":"Adjei","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0630","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2174\/138161210791164108","article-title":"Potential of nanoparticulate drug delivery systems by intranasal administration","volume":"16","author":"Ali","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2014.03.004_b0635","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2007.04.007","article-title":"Solid lipid nanoparticles as a drug delivery system for peptides and proteins","volume":"59","author":"Almeida","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.03.004_b0640","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0167-7799(91)90091-U","article-title":"The nasal delivery of peptides and proteins","volume":"9","author":"Illum","year":"1991","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0645","first-page":"56","article-title":"New modes of administration of salmon calcitonin in Paget\u2019s disease. Nasal spray and suppository","volume":"217","author":"Nagant de Deuxchaisnes","year":"1987","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0650","first-page":"35","article-title":"Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine","volume":"7","author":"O\u2019Hagan","year":"1990","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2014.03.004_b0655","first-page":"195","article-title":"Nonparenteral administration of peptide and protein drugs","volume":"3","author":"Siddiqui","year":"1987","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2014.03.004_b0660","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/17425247.2012.636801","article-title":"Physicochemical and physiological considerations for efficient nose-to-brain targeting","volume":"9","author":"Bahadur","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0665","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0670","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17425247.2.2.281","article-title":"Advances in nasal drug delivery through tight junction technology","volume":"2","author":"Johnson","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0675","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/17425240902902315","article-title":"Tight junction modulator and drug delivery","volume":"6","author":"Matsuhisa","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0680","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.biomaterials.2004.06.020","article-title":"Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption","volume":"26","author":"Smith","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2014.03.004_b0685","first-page":"21","article-title":"Advances in nasal trans-mucosal drug delivery","volume":"1","author":"Kushwaha","year":"2011","journal-title":"J Appl. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0690","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2337\/db10-0329","article-title":"Intranasal insulin enhances postprandial thermogenesis and lowers postpranial serum insulin levels in healthy men","volume":"60","author":"Benedict","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2014.03.004_b0695","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/10717541003762888","article-title":"Nasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride","volume":"17","author":"du Plessis","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0700","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.10.5.573","article-title":"Long-term use of intranasal insulin in insulin-dependent diabetic patients","volume":"10","author":"Frauman","year":"1987","journal-title":"Diabetes Care."},{"key":"10.1016\/j.ejpb.2014.03.004_b0705","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2337\/db11-1390","article-title":"Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women","volume":"61","author":"Hallschmid","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2014.03.004_b0710","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nut.2009.08.001","article-title":"Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action","volume":"26","author":"Henkin","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.ejpb.2014.03.004_b0715","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/BF00401839","article-title":"Intranasal insulin therapy: the clinical realities","volume":"38","author":"Hilsted","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejpb.2014.03.004_b0720","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2337\/diab.32.11.1040","article-title":"Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects","volume":"32","author":"Moses","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2014.03.004_b0725","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ejpb.2007.08.009","article-title":"Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles","volume":"68","author":"Zhang","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0730","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/17425247.2011.540236","article-title":"Intranasal erythropoietin therapy in nervous system disorders","volume":"8","author":"Genc","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0735","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1248\/bpb.18.734","article-title":"Effects of dose, pH and osmolarity on intranasal absorption of recombinant human erythropoietin in rats","volume":"18","author":"Shimoda","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2014.03.004_b0740","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neulet.2005.07.008","article-title":"Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia","volume":"387","author":"Yu","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejpb.2014.03.004_b0745","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1015885204249","article-title":"The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models","volume":"7","author":"Baldwin","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0750","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2004.08.001","article-title":"Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer\/glutathione microparticulate delivery system","volume":"100","author":"Leitner","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0755","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0015-0282(16)49395-7","article-title":"Luteinizing hormone and follicle-stimulating hormone responses to intranasal gonadotropin-releasing hormone","volume":"45","author":"Rajfer","year":"1986","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ejpb.2014.03.004_b0760","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1211\/jpp.58.1.0003","article-title":"Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in rats","volume":"58","author":"Shahiwala","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0765","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijpharm.2012.02.044","article-title":"Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization","volume":"428","author":"Shahnaz","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0770","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(97)00062-8","article-title":"Peptide hormones: review of current and emerging uses by nasal delivery","volume":"29","author":"Pontiroli","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.03.004_b0775","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0780","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2009.12.060","article-title":"The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides","volume":"388","author":"Khafagy","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0785","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1128\/JVI.02453-08","article-title":"Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets","volume":"83","author":"Kugel","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0790","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1081\/ERC-200035957","article-title":"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1\u201334)], teriparatide in rats","volume":"30","author":"Agu","year":"2004","journal-title":"Endocr. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0795","first-page":"64","article-title":"Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1\u201334)","volume":"17","author":"Sato","year":"2007","journal-title":"Clin. Calcium"},{"key":"10.1016\/j.ejpb.2014.03.004_b0800","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2009.10.031","article-title":"Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid\u2122 fatty acid based delivery system, and by N-trimethyl chitosan chloride","volume":"385","author":"du Plessis","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b0805","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/s12248-010-9242-9","article-title":"Scientific considerations for generic synthetic salmon calcitonin nasal spray products","volume":"13","author":"Lee","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2014.03.004_b0810","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00024677-200403020-00006","article-title":"Calcitonin therapy in osteoporosis","volume":"2004","author":"Mu\u00f1oz-Torres","year":"2004","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0815","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/ajg.2011.129","article-title":"Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial: does nasal calcitonin improve bone density in youth with IBD?","volume":"106","author":"Pappa","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0820","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002512-199608050-00006","article-title":"Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis","volume":"8","author":"Plosker","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejpb.2014.03.004_b0825","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/jps.21690","article-title":"Development of calcitonin salmon nasal spray: similarity of peptide formulated in chlorobutanolcompared to benzalkonium chloride as preservative","volume":"98","author":"Constantino","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b1240","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejpb.2014.03.004_b0835","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","article-title":"Salmon calcitonin: a review of current and future therapeutic indications","volume":"19","author":"Chesnut","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejpb.2014.03.004_b0840","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00002512-199101050-00007","article-title":"Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging","volume":"1","author":"Clissold","year":"1991","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejpb.2014.03.004_b0845","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0928-0987(01)00094-X","article-title":"Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin","volume":"13","author":"Morimoto","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0850","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jps.10537","article-title":"Stability of PEGylated salmon calcitonin in nasal mucosa","volume":"93","author":"Na","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b0855","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1211\/0022357056073","article-title":"Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep","volume":"57","author":"Hinchcliffe","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0860","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2005.09.047","article-title":"Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant","volume":"110","author":"Matsuyama","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0865","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2006.08.004","article-title":"Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-l-cysteine as a mucolytic agent","volume":"115","author":"Matsuyama","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b0870","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.peptides.2009.03.018","article-title":"Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery","volume":"30","author":"Chen","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.ejpb.2014.03.004_b0875","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the ORACAL trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0880","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1517\/14712598.2010.526104","article-title":"Oral salmon calcitonin-pharmacology in osteoporosis","volume":"10","author":"Henriksen","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejpb.2014.03.004_b0885","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/10717544.2011.596585","article-title":"N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin","volume":"18","author":"Huang","year":"2011","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b0890","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.joca.2011.01.008","article-title":"Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover","volume":"19","author":"Nielsen","year":"2011","journal-title":"Osteoarthr. Cartilage"},{"key":"10.1016\/j.ejpb.2014.03.004_b0895","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrendo.2011.100","article-title":"Familial forms of diabetes insipidus: clinical and molecular characteristics","volume":"7","author":"Babey","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0900","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","article-title":"The vasopressin system: physiology and clinical strategies","volume":"105","author":"Treschan","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejpb.2014.03.004_b0905","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00467-011-1762-8","article-title":"Nocturnal enuresis\u2014theoretic background and practical guidelines","volume":"26","author":"Nev\u00e9us","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0910","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.juro.2007.03.015","article-title":"The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis","volume":"178","author":"Robson","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0915","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ando.2011.09.001","article-title":"Treatment of neurogenic diabetes insipidus","volume":"72","author":"Chanson","year":"2011","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"10.1016\/j.ejpb.2014.03.004_b0920","first-page":"377","article-title":"The use of desmopressin in acquired haemophilia A: a systematic review","volume":"9","author":"Franchini","year":"2011","journal-title":"Blood Transfus."},{"key":"10.1016\/j.ejpb.2014.03.004_b0925","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/000992289303200105","article-title":"Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe","author":"Hj\u00e4lm\u00e5s","year":"1993","journal-title":"Clin. Pediatr. (Phila.)"},{"key":"10.1016\/j.ejpb.2014.03.004_b0930","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/pgmj.2006.052118","article-title":"How do you treat bleeding disorders with desmopressin?","volume":"83","author":"Ozg\u00f6nenel","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejpb.2014.03.004_b0935","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/157488607781668891","article-title":"Desmopressin 30 years in clinical use: a safety review","volume":"2","author":"Van de Walle","year":"2007","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ejpb.2014.03.004_b0940","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11319110-000000000-00000","article-title":"Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues","volume":"33","author":"Van de Walle","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejpb.2014.03.004_b0945","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s11095-009-9871-9","article-title":"Clinical study shows improved absorption of desmopressin with novel formulation","volume":"26","author":"Frans\u00e9n","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0950","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2826.2011.02130.x","article-title":"Physiology of the gonadotrophin-releasing hormone (GnRH) neurone: studies from embryonic GnRH neurons","volume":"23","author":"Constantin","year":"2011","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0955","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2010.09.066","article-title":"Identified GnRH neuron electrophysiology: a decade of study","volume":"1364","author":"Moenter","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b0960","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yfrne.2010.07.005","article-title":"Gonadotropin-releasing hormone (GnRH) neuron migration: initiation, maintenance and cessation as critical steps to ensure normal reproductive function","volume":"32","author":"Wierman","year":"2011","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0965","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000314193","article-title":"Human GnRH deficiency: a unique disease model to unravel the ontogeny of GnRH neurons","volume":"92","author":"Balasubramanian","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejpb.2014.03.004_b0970","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1258\/0007142001903346","article-title":"Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: therapeutic implications","volume":"56","author":"Millar","year":"2000","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ejpb.2014.03.004_b0975","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1464-410X.2011.10370.x","article-title":"Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer","volume":"109","author":"Shore","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.ejpb.2014.03.004_b0980","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.urology.2011.11.019","article-title":"Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109","volume":"79","author":"Berglund","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ejpb.2014.03.004_b0985","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2490-11-15","article-title":"A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients","volume":"11","author":"Tunn","year":"2011","journal-title":"BMC Urol."},{"key":"10.1016\/j.ejpb.2014.03.004_b0990","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1093\/humrep\/dem223","article-title":"Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI\/embryo transfer: a randomized double-blind clinical trial (NCT00461916)","volume":"22","author":"Safdarian","year":"2007","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ejpb.2014.03.004_b0995","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0015-0282(01)01977-X","article-title":"A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection","volume":"76","author":"Takeuchi","year":"2001","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ejpb.2014.03.004_b1000","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1013108921427","article-title":"Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program","volume":"18","author":"Franco","year":"2001","journal-title":"J. Assist. Reprod. Genet."},{"key":"10.1016\/j.ejpb.2014.03.004_b1005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000057943","article-title":"Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist","volume":"57","author":"Tuvemo","year":"2002","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b1010","first-page":"S14","article-title":"Pharmaceutical aspects. Nasal and depot formulations of leuprolide","volume":"8","author":"Shimamoto","year":"1987","journal-title":"J. Androl."},{"key":"10.1016\/j.ejpb.2014.03.004_b1015","first-page":"127","article-title":"Oxytocin: the great facilitator of life","volume":"88","author":"Lee","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1020","first-page":"875","article-title":"Prevention and management of postpartum hemorrhage","volume":"75","author":"Anderson","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.ejpb.2014.03.004_b1025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajog.2010.03.007","article-title":"High-dose vs low-dose oxytocin for labor augmentation: a systematic review","volume":"203","author":"Wei","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/01443610050009502","article-title":"Variations in oxytocin regimes in Scottish labour wards in 1998","volume":"20","author":"Arnott","year":"2000","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1035","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1471-0528.2012.03341.x","article-title":"Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial","volume":"119","author":"Bellad","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.ejpb.2014.03.004_b1040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/AOG.0b013e3182220192","article-title":"Oxytocin regimen for labor augmentation, labor progression, and perinatal outcomes","volume":"118","author":"Zhang","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1045","doi-asserted-by":"crossref","first-page":"F169","DOI":"10.1136\/adc.2005.081265","article-title":"Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants","volume":"91","author":"Fewtrell","year":"2006","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"key":"10.1016\/j.ejpb.2014.03.004_b1050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/bmj.283.6287.340","article-title":"Oxytocin enhances onset of lactation among mothers delivering prematurely","volume":"283","author":"Ruis","year":"1981","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ejpb.2014.03.004_b1055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2011.07.027","article-title":"Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia","volume":"132","author":"Pedersen","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b1060","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awr171","article-title":"The effects of oxytocin on social cognition and behaviour in frontotemporal dementia","volume":"134","author":"Jesso","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ejpb.2014.03.004_b1065","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.psyneuen.2011.03.013","article-title":"Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study","volume":"36","author":"Simeon","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejpb.2014.03.004_b1070","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/npp.2010.123","article-title":"Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder","volume":"35","author":"Labuschagne","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejpb.2014.03.004_b1075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0169-409X(98)00073-8","article-title":"Intranasal insulin delivery and therapy","volume":"35","author":"Hinchcliffe","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.03.004_b1080","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1464-5491.2001.00528.x","article-title":"Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over study","volume":"18","author":"Lalej-Bennis","year":"2001","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejpb.2014.03.004_b1085","first-page":"372","article-title":"Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance","volume":"27","author":"Lalej-Bennis","year":"2001","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejpb.2014.03.004_b1090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nut.2009.08.001","article-title":"Inhaled insulin \u2013 intrapulmonary, intranasal, and other routes of administration: mechanisms of action","volume":"26","author":"Henkin","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.ejpb.2014.03.004_b1095","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1211\/jpp.62.05.0004","article-title":"Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats","volume":"62","author":"Jintapattanakit","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1100","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1023\/A:1018908705446","article-title":"Enhancement of nasal absorption of insulin using chitosan nanoparticles","volume":"16","author":"Fern\u00e1ndez-Urrusuno","year":"1999","journal-title":"Pharmac. Res."},{"key":"10.1016\/j.ejpb.2014.03.004_b1105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2010.08.004","article-title":"Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies","volume":"148","author":"Sintov","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2014.03.004_b1110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/1061186X.2012.693499","article-title":"Strategies for non-invasive delivery of biologics","volume":"20","author":"Chung","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2014.03.004_b1115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejpb.2010.11.022","article-title":"Thermosensitive hydrogels for nasal drug delivery: the formulation and characterization of systems based on N-trimethyl chitosan chloride","volume":"77","author":"Nazar","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b1120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2014.03.004_b1125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.addr.2009.11.012","article-title":"Nanotechnology solutions for mucosal immunization","volume":"62","author":"Chadwick","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.03.004_b1130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.biotechadv.2009.06.007","article-title":"Application of chitosan microspheres for nasal delivery of vaccines","volume":"27","author":"Kang","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2014.03.004_b1135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/156720106777731019","article-title":"Liposomes and micro\/nanoparticles as colloidal carriers for nasal drug delivery","volume":"3","author":"Mainardes","year":"2006","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b1140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/156720110791011846","article-title":"Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response","volume":"7","author":"Zaman","year":"2010","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2014.03.004_b1145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/14760584.4.2.185","article-title":"Nanoparticles as carriers for nasal vaccine delivery","volume":"4","author":"K\u00f6ping-H\u00f6gg\u00e5rd","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2014.03.004_b1150","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jps.21493","article-title":"Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems","volume":"98","author":"Sharma","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b1155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4161\/bbug.1.5.12086","article-title":"Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections","volume":"1","author":"Medina","year":"2010","journal-title":"Bioeng. Bugs"},{"key":"10.1016\/j.ejpb.2014.03.004_b1160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00109-010-0696-0","article-title":"Development of adenoviral vector-based mucosal vaccine against influenza","volume":"89","author":"Tutykhina","year":"2011","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejpb.2014.03.004_b1165","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1586\/erv.11.141","article-title":"Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases","volume":"10","author":"Zhang","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2014.03.004_b1170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4161\/bbug.2.6.18167","article-title":"Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route","volume":"2","author":"Li","year":"2011","journal-title":"Bioeng. Bugs"},{"key":"10.1016\/j.ejpb.2014.03.004_b1175","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-food-022510-133640","article-title":"Mucosal vaccination and therapy with genetically modified lactic acid bacteria","volume":"2","author":"Wells","year":"2011","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1128\/CVI.00354-10","article-title":"Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine","volume":"18","author":"Simon","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1185","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1016\/j.vaccine.2008.03.098","article-title":"Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice","volume":"26","author":"Hinkula","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2014.03.004_b1190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2011.04.029","article-title":"Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen","volume":"413","author":"Tiwari","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.03.004_b1195","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.vaccine.2008.02.023","article-title":"Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli","volume":"26","author":"Brun","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2014.03.004_b1200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1472-6750-10-77","article-title":"Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis","volume":"10","author":"Lorenzi","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable dry powder formulation for nasal delivery of anthrax vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.03.004_b1210","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.biomaterials.2011.11.068","article-title":"Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization","volume":"33","author":"Wu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2014.03.004_b1215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/CVI.00263-10","article-title":"Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumonia","volume":"18","author":"Xu","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ejpb.2014.03.004_b1220","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1016\/j.vaccine.2011.05.027","article-title":"Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine","volume":"29","author":"Velasquez","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2014.03.004_b1225","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1016\/j.vaccine.2010.06.086","article-title":"Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers","volume":"28","author":"Tribble","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2014.03.004_b1230","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2567.2007.02702.x","article-title":"Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery","volume":"123","author":"Goodsell","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.ejpb.2014.03.004_b1235","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1089\/hum.2005.16.1014","article-title":"Gendicine: the first commercial gene therapy product","volume":"16","author":"Wilson","year":"2005","journal-title":"Hum. Gene Ther."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T21:04:34Z","timestamp":1565298274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641114000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":247,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0939641114000812"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.03.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}